{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:00:30Z","timestamp":1790766030452,"version":"4.1.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1124\/pharmrev.120.000149","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T21:10:12Z","timestamp":1614978612000},"page":"763-791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications"],"prefix":"10.1016","volume":"73","author":[{"given":"Jaclyn N.","family":"Highland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panos","family":"Zanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lace M.","family":"Riggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polymnia","family":"Georgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruin","family":"Moaddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna F.R.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd D.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pharmrev.120.000149_bib1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1124\/mol.120.119784","article-title":"Hydroxynorketamine blocks N-methyl-d-aspartate receptor currents by binding to closed receptors","volume":"98","author":"Abbott","year":"2020","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pharmrev.120.000149_bib2","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.biopsych.2017.01.002","article-title":"What\u2019s the buzz about hydroxynorketamine? Is it the history, the story, the debate, or the promise?","volume":"81","author":"Abdallah","year":"2017","journal-title":"Biol Psychiatry"},{"key":"10.1124\/pharmrev.120.000149_bib3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/s41386-020-0668-1","article-title":"(2R,6R)-Hydroxynorketamine (HNK) plasma level predicts poor antidepressant response: is this the end of the HNK pipeline?","volume":"45","author":"Abdallah","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.120.000149_bib4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/bms.1200081103","article-title":"Studies on the biotransformation of ketamine. 1-Identification of metabolites produced in vitro from rat liver microsomal preparations","volume":"8","author":"Adams","year":"1981","journal-title":"Biomed Mass Spectrom"},{"key":"10.1124\/pharmrev.120.000149_bib5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/ijnp\/pyz041","article-title":"(R)-ketamine induces a greater increase in prefrontal 5-HT release than (S)-ketamine and ketamine metabolites via an AMPA receptor-independent mechanism","volume":"22","author":"Ago","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1124\/pharmrev.120.000149_bib6","article-title":"Antidepressant actions of ketamine engage cell-specific translation via eIF4E","author":"Aguilar-Valles","year":"2020","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000149_bib7","article-title":"Hydroxynorketamine: implications for the NMDA receptor hypothesis of ketamine\u2019s antidepressant action","volume":"1","author":"Aleksandrova","year":"2017","journal-title":"Chronic Stress (Thousand Oaks)"},{"key":"10.1124\/pharmrev.120.000149_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neubiorev.2019.07.007","article-title":"Evaluation of the Wistar-Kyoto rat model of depression and the role of synaptic plasticity in depression and antidepressant response","volume":"105","author":"Aleksandrova","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1124\/pharmrev.120.000149_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13041-020-00627-z","article-title":"Ketamine and its metabolite, (2R,6R)-HNK, restore hippocampal LTP and long-term spatial memory in the Wistar-Kyoto rat model of depression","volume":"13","author":"Aleksandrova","year":"2020","journal-title":"Mol Brain"},{"key":"10.1124\/pharmrev.120.000149_bib10","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1523\/JNEUROSCI.19-07-02693.1999","article-title":"Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices","volume":"19","author":"Alkondon","year":"1999","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000149_bib11","doi-asserted-by":"crossref","first-page":"100239","DOI":"10.1016\/j.ynstr.2020.100239","article-title":"The stress susceptibility factor FKBP51 controls S-ketamine-evoked release of mBDNF in the prefrontal cortex of mice","volume":"13","author":"Anderzhanova","year":"2020","journal-title":"Neurobiol Stress"},{"key":"10.1124\/pharmrev.120.000149_bib12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1476-5381.1983.tb11031.x","article-title":"The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate","volume":"79","author":"Anis","year":"1983","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.120.000149_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1124\/pharmrev.120.000149_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrn1846","article-title":"New approaches to antidepressant drug discovery: beyond monoamines","volume":"7","author":"Berton","year":"2006","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/pharmrev.120.000149_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/jpet.116.235838","article-title":"Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters","volume":"359","author":"Can","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.120.000149_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.01.034","article-title":"Antidepressant drugs act by directly binding to TRKB neurotrophin receptors","author":"Casarotto","year":"2021","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000149_bib16","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/mp.2017.241","article-title":"Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling","volume":"23","author":"Cavalleri","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.1124\/pharmrev.120.000149_bib17","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/ijnp\/pyy053","article-title":"No sex-specific differences in the acute antidepressant actions of (R)-ketamine in an inflammation model","volume":"21","author":"Chang","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1124\/pharmrev.120.000149_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00004311-197412020-00018","article-title":"Biotransformation and disposition of ketamine","volume":"12","author":"Chang","year":"1974","journal-title":"Int Anesthesiol Clin"},{"key":"10.1124\/pharmrev.120.000149_bib19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3389\/fncel.2014.00401","article-title":"The role of AMPA receptors in postsynaptic mechanisms of synaptic plasticity","volume":"8","author":"Chater","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"10.1124\/pharmrev.120.000149_bib20","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41386-020-0714-z","article-title":"Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine","volume":"45","author":"Chen","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.120.000149_bib21","doi-asserted-by":"crossref","first-page":"108068","DOI":"10.1016\/j.neuropharm.2020.108068","article-title":"Brain-derived neurotrophic factor in the ventrolateral periaqueductal gray contributes to (2R,6R)-hydroxynorketamine-mediated actions","volume":"170","author":"Chou","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.120.000149_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.06.033","article-title":"(2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray","volume":"139","author":"Chou","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.120.000149_bib23","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/WNR.0000000000001131","article-title":"(2R,6R)-Hydroxynorketamine promotes dendrite outgrowth in human inducible pluripotent stem cell-derived neurons through AMPA receptor with timing and exposure compatible with ketamine infusion pharmacokinetics in humans","volume":"29","author":"Collo","year":"2018","journal-title":"Neuroreport"},{"key":"10.1124\/pharmrev.120.000149_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrn2055","article-title":"Regulatory mechanisms of AMPA receptors in synaptic plasticity","volume":"8","author":"Derkach","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/pharmrev.120.000149_bib25","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3109\/00498254.2012.685777","article-title":"Stereoselective and regiospecific hydroxylation of ketamine and norketamine","volume":"42","author":"Desta","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/pharmrev.120.000149_bib26","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4088\/JCP.09m05327blu","article-title":"Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder","volume":"71","author":"DiazGranados","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/pharmrev.120.000149_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/20961790.2017.1285219","article-title":"Metabolism and metabolomics of ketamine: a toxicological approach","volume":"2","author":"Dinis-Oliveira","year":"2017","journal-title":"Forensic Sci Res"},{"key":"10.1124\/pharmrev.120.000149_bib28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1113\/jphysiol.2006.124958","article-title":"Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block","volume":"581","author":"Dravid","year":"2007","journal-title":"J Physiol"},{"key":"10.1124\/pharmrev.120.000149_bib29","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/bmc.1379","article-title":"Metabolic stability and determination of cytochrome P450 isoenzymes\u2019 contribution to the metabolism of medetomidine in dog liver microsomes","volume":"24","author":"Duhamel","year":"2010","journal-title":"Biomed Chromatogr"},{"key":"10.1124\/pharmrev.120.000149_bib30","first-page":"15","article-title":"Cardiovascular and autonomic effects of sevoflurane","volume":"47","author":"Ebert","year":"1996","journal-title":"Acta Anaesthesiol Belg"},{"issue":"Suppl","key":"10.1124\/pharmrev.120.000149_bib31","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/00000539-199512001-00003","article-title":"Cardiovascular responses to sevoflurane: a review","volume":"81","author":"Ebert","year":"1995","journal-title":"Anesth Analg"},{"key":"10.1124\/pharmrev.120.000149_bib32","doi-asserted-by":"crossref","first-page":"172973","DOI":"10.1016\/j.pbb.2020.172973","article-title":"Ketamine metabolite (2R,6R)-hydroxynorketamine reverses behavioral despair produced by adolescent trauma","volume":"196","author":"Elmer","year":"2020","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.120.000149_bib33","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.bbagen.2018.03.008","article-title":"Stereochemical and structural effects of (2R,6R)-hydroxynorketamine on the mitochondrial metabolome in PC-12 cells","volume":"1862","author":"Faccio","year":"2018","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1124\/pharmrev.120.000149_bib34","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41386-020-0663-6","article-title":"Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression [published correction appears in Neuropsychopharmacology (2020)]","volume":"45","author":"Farmer","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.120.000149_bib35","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jpba.2017.09.007","article-title":"Ketamine metabolites with antidepressant effects: fast, economical, and eco-friendly enantioselective separation based on supercritical-fluid chromatography (SFC) and single quadrupole MS detection","volume":"146","author":"Fassauer","year":"2017","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/pharmrev.120.000149_bib36","doi-asserted-by":"crossref","first-page":"18150","DOI":"10.1074\/jbc.RA119.008837","article-title":"Pharmacologically diverse antidepressants facilitate TRKB receptor activation by disrupting its interaction with the endocytic adaptor complex AP-2","volume":"294","author":"Fred","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000149_bib37","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1073\/pnas.1814709116","article-title":"Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine","volume":"116","author":"Fukumoto","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000149_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.116.239228","article-title":"Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine","volume":"361","author":"Fukumoto","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.120.000149_bib39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev-pharmtox-010617-052811","article-title":"Molecular pharmacology and neurobiology of rapid-acting antidepressants","volume":"59","author":"Gould","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/pharmrev.120.000149_bib40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jpsychires.2019.08.005","article-title":"Ketamine metabolite pilot study in a suicidal depression trial","volume":"117","author":"Grunebaum","year":"2019","journal-title":"J Psychiatr Res"},{"key":"10.1124\/pharmrev.120.000149_bib41","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1085\/jgp.201812032","article-title":"Structure, function, and allosteric modulation of NMDA receptors","volume":"150","author":"Hansen","year":"2018","journal-title":"J Gen Physiol"},{"key":"10.1124\/pharmrev.120.000149_bib42","doi-asserted-by":"crossref","first-page":"107947","DOI":"10.1016\/j.neuropharm.2020.107947","article-title":"Ketamine increases vmPFC activity: effects of (R)- and (S)-stereoisomers and (2R,6R)-hydroxynorketamine metabolite","volume":"166","author":"Hare","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.120.000149_bib43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jpba.2017.02.035","article-title":"Quantitative chiral and achiral determination of ketamine and its metabolites by LC-MS\/MS in human serum, urine and fecal samples","volume":"139","author":"Hasan","year":"2017","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/pharmrev.120.000149_bib44","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3390\/ijms21062142","article-title":"Sexually dimorphic behavioral profile in a transgenic model enabling targeted recombination in active neurons in response to ketamine and (2R,6R)-hydroxynorketamine administration","volume":"21","author":"Herzog","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1124\/pharmrev.120.000149_bib45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0269881118812095","article-title":"Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine","volume":"33","author":"Highland","year":"2019","journal-title":"J Psychopharmacol"},{"key":"10.1124\/pharmrev.120.000149_bib46","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1111\/bph.14785","article-title":"What role does the (2R,6R)-hydronorketamine metabolite play in the antidepressant-like and abuse-related effects of (R)-ketamine?","volume":"176","author":"Hillhouse","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.120.000149_bib47","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bcp.2018.03.032","article-title":"Ketamine and ketamine metabolites as novel estrogen receptor ligands: induction of cytochrome P450 and AMPA glutamate receptor gene expression","volume":"152","author":"Ho","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pharmrev.120.000149_bib48","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3389\/fphar.2019.01302","article-title":"Ketamine and active ketamine metabolites regulate STAT3 and the type I interferon pathway in human microglia: molecular mechanisms linked to the antidepressant effects of ketamine","volume":"10","author":"Ho","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1124\/pharmrev.120.000149_bib49","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.bja.2020.06.067","article-title":"Pharmacokinetics of ketamine and its major metabolites norketamine, hydroxynorketamine, and dehydronorketamine: a model-based analysis","volume":"125","author":"Kamp","year":"2020","journal-title":"Br J Anaesth"},{"key":"10.1124\/pharmrev.120.000149_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/2398212820957847","article-title":"(2S,6S)- and (2R,6R)-hydroxynorketamine inhibit the induction of NMDA receptor-dependent LTP at hippocampal CA1 synapses in mice","volume":"4","author":"Kang","year":"2020","journal-title":"Brain Neurosci Adv"},{"key":"10.1124\/pharmrev.120.000149_bib51","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/npp.2017.210","article-title":"The ketamine metabolite 2R,6R-hydroxynorketamine blocks NMDA receptors and impacts downstream signaling linked to antidepressant effects","volume":"43","author":"Kavalali","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.120.000149_bib52","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.neuron.2020.05.015","article-title":"Targeting homeostatic synaptic plasticity for treatment of mood disorders","volume":"106","author":"Kavalali","year":"2020","journal-title":"Neuron"},{"key":"10.1124\/pharmrev.120.000149_bib53","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/00000542-199212000-00022","article-title":"Metabolism of ketamine stereoisomers by human liver microsomes","volume":"77","author":"Kharasch","year":"1992","journal-title":"Anesthesiology"},{"key":"10.1124\/pharmrev.120.000149_bib54","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fnins.2020.00254","article-title":"The ventrolateral periaqueductal gray contributes to depressive-like behaviors in recovery of inflammatory bowel disease rat model","volume":"14","author":"Ko","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1124\/pharmrev.120.000149_bib55","doi-asserted-by":"crossref","first-page":"107684","DOI":"10.1016\/j.neuropharm.2019.107684","article-title":"Ketamine-induced regulation of TrkB-GSK3\u03b2 signaling is accompanied by slow EEG oscillations and sedation but is independent of hydroxynorketamine metabolites","volume":"157","author":"Kohtala","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.120.000149_bib56","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/rapm-2018-000013","article-title":"Efficacy of the ketamine metabolite (2R,6R)-hydroxynorketamine in mice models of pain","volume":"44","author":"Kroin","year":"2019","journal-title":"Reg Anesth Pain Med"},{"key":"10.1124\/pharmrev.120.000149_bib57","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1124\/pharmrev.120.000149_bib58","doi-asserted-by":"crossref","first-page":"122214","DOI":"10.1016\/j.jchromb.2020.122214","article-title":"Targeted mass spectrometry of ketamine and its metabolites cis-6-hydroxynorketamine and norketamine in human blood serum","volume":"1152","author":"Kurzweil","year":"2020","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/pharmrev.120.000149_bib59","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2885.2006.00794.x","article-title":"Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses","volume":"29","author":"Lankveld","year":"2006","journal-title":"J Vet Pharmacol Ther"},{"key":"10.1124\/pharmrev.120.000149_bib60","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1021\/jm00161a043","article-title":"Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine","volume":"29","author":"Leung","year":"1986","journal-title":"J Med Chem"},{"key":"10.1124\/pharmrev.120.000149_bib61","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bcpt.12941","article-title":"Interactions of (2S,6S;2R,6R)-Hydroxynorketamine, a secondary metabolite of (R,S)-Ketamine, with morphine","volume":"122","author":"Lilius","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pharmrev.120.000149_bib62","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0304-3940(82)90330-5","article-title":"Effects of optical isomers of ketamine on excitation of cat and rat spinal neurones by amino acids and acetylcholine","volume":"29","author":"Lodge","year":"1982","journal-title":"Neurosci Lett"},{"key":"10.1124\/pharmrev.120.000149_bib63","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1073\/pnas.1816071116","article-title":"Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function","volume":"116","author":"Lumsden","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000149_bib64","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1152\/jn.1987.58.2.251","article-title":"Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine","volume":"58","author":"MacDonald","year":"1987","journal-title":"J Neurophysiol"},{"key":"10.1124\/pharmrev.120.000149_bib65","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1039\/C6CC09061C","article-title":"Gauging circadian variation in ketamine metabolism by real-time breath analysis","volume":"53","author":"Martinez-Lozano Sinues","year":"2017","journal-title":"Chem Commun (Camb)"},{"key":"10.1124\/pharmrev.120.000149_bib66","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13211","article-title":"The novel antidepressant ketamine enhances dentate gyrus proliferation with no effects on synaptic plasticity or hippocampal function in depressive-like rats","volume":"225","author":"Micha\u00eblsson","year":"2019","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1124\/pharmrev.120.000149_bib67","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejphar.2012.11.023","article-title":"Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in \u03b17 nicotinic acetylcholine receptors","volume":"698","author":"Moaddel","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.120.000149_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.157","article-title":"The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats","volume":"3","author":"Moaddel","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1124\/pharmrev.120.000149_bib69","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jpba.2016.03.030","article-title":"Subchronic administration of (R,S)-ketamine induces ketamine ring hydroxylation in Wistar rats","volume":"127","author":"Moaddel","year":"2016","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/pharmrev.120.000149_bib70","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.talanta.2010.08.005","article-title":"A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome","volume":"82","author":"Moaddel","year":"2010","journal-title":"Talanta"},{"key":"10.1124\/pharmrev.120.000149_bib71","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1021\/acs.orglett.7b02177","article-title":"Synthesis and N-Methyl-d-aspartate (NMDA) receptor activity of ketamine metabolites","volume":"19","author":"Morris","year":"2017","journal-title":"Org Lett"},{"key":"10.1124\/pharmrev.120.000149_bib72","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nrn2174","article-title":"Neural mechanisms of aggression","volume":"8","author":"Nelson","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/pharmrev.120.000149_bib73","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/00000542-199704000-00021","article-title":"Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors","volume":"86","author":"Orser","year":"1997","journal-title":"Anesthesiology"},{"key":"10.1124\/pharmrev.120.000149_bib74","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/ALN.0000000000000285","article-title":"(R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function","volume":"121","author":"Paul","year":"2014","journal-title":"Anesthesiology"},{"key":"10.1124\/pharmrev.120.000149_bib75","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.biopsych.2017.10.020","article-title":"Common neurotransmission recruited in (R,S)-Ketamine and (2R,6R)-hydroxynorketamine-induced sustained antidepressant-like effects","volume":"84","author":"Pham","year":"2018","journal-title":"Biol Psychiatry"},{"key":"10.1124\/pharmrev.120.000149_bib76","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1016\/j.chroma.2010.06.028","article-title":"Enantioselective capillary electrophoresis for identification and characterization of human cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro","volume":"1217","author":"Portmann","year":"2010","journal-title":"J Chromatogr A"},{"key":"10.1124\/pharmrev.120.000149_bib77","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/da.22253","article-title":"Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression","volume":"31","author":"Price","year":"2014","journal-title":"Depress Anxiety"},{"key":"10.1124\/pharmrev.120.000149_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/prca.201900094","article-title":"Proteomic study reveals the involvement of energy metabolism in the fast antidepressant effect of (2R, 6R)-hydroxy norketamine","volume":"14","author":"Rahman","year":"2020","journal-title":"Proteomics Clin Appl"},{"key":"10.1124\/pharmrev.120.000149_bib79","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/ALN.0000000000001392","article-title":"Role of cytochrome P4502B6 polymorphisms in ketamine metabolism and clearance","volume":"125","author":"Rao","year":"2016","journal-title":"Anesthesiology"},{"key":"10.1124\/pharmrev.120.000149_bib80","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41386-019-0443-3","article-title":"(2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism","volume":"45","author":"Riggs","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.120.000149_bib81","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept","volume":"38","author":"Rodriguez","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.120.000149_bib82","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.chroma.2016.07.060","article-title":"Pharmacokinetics of ketamine and three metabolites in Beagle dogs under sevoflurane vs. medetomidine comedication assessed by enantioselective capillary electrophoresis","volume":"1467","author":"Sandbaumh\u00fcter","year":"2016","journal-title":"J Chromatogr A"},{"key":"10.1124\/pharmrev.120.000149_bib83","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/elps.201700017","article-title":"Effect of the \u03b12 -receptor agonists medetomidine, detomidine, xylazine, and romifidine on the ketamine metabolism in equines assessed with enantioselective capillary electrophoresis","volume":"38","author":"Sandbaumh\u00fcter","year":"2017","journal-title":"Electrophoresis"},{"key":"10.1124\/pharmrev.120.000149_bib84","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1002\/elps.201500147","article-title":"Effects of medetomidine and its active enantiomer dexmedetomidine on N-demethylation of ketamine in canines determined in vitro using enantioselective capillary electrophoresis","volume":"36","author":"Sandbaumh\u00fcter","year":"2015","journal-title":"Electrophoresis"},{"key":"10.1124\/pharmrev.120.000149_bib85","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/elps.201700016","article-title":"Separation of hydroxynorketamine stereoisomers using capillary electrophoresis with sulfated \u03b2-cyclodextrin and highly sulfated \u03b3-cyclodextrin","volume":"38","author":"Sandbaumh\u00fcter","year":"2017","journal-title":"Electrophoresis"},{"key":"10.1124\/pharmrev.120.000149_bib86","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/elps.201800012","article-title":"Enantioselective capillary electrophoresis provides insight into the phase II metabolism of ketamine and its metabolites in vivo and in vitro","volume":"39","author":"Sandbaumh\u00fcter","year":"2018","journal-title":"Electrophoresis"},{"key":"10.1124\/pharmrev.120.000149_bib87","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/da.22536","article-title":"A review of ketamine abuse and diversion","volume":"33","author":"Sassano-Higgins","year":"2016","journal-title":"Depress Anxiety"},{"key":"10.1124\/pharmrev.120.000149_bib88","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.mcn.2018.05.002","article-title":"Functional organization of postsynaptic glutamate receptors","volume":"91","author":"Scheefhals","year":"2018","journal-title":"Mol Cell Neurosci"},{"key":"10.1124\/pharmrev.120.000149_bib89","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1002\/elps.200900221","article-title":"CE provides evidence of the stereoselective hydroxylation of norketamine in equines","volume":"30","author":"Schmitz","year":"2009","journal-title":"Electrophoresis"},{"key":"10.1124\/pharmrev.120.000149_bib90","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-3565(24)29296-X","article-title":"Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system","volume":"299","author":"Schoepp","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.120.000149_bib91","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.neuropharm.2019.04.019","article-title":"Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine","volume":"153","author":"Shaffer","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.120.000149_bib92","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/ijnp\/pyx108","article-title":"Lack of antidepressant effects of (2R,6R)-hydroxynorketamine in a rat learned helplessness model: comparison with (R)-ketamine","volume":"21","author":"Shirayama","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1124\/pharmrev.120.000149_bib93","article-title":"Ketamine metabolites enantioselectively decrease intracellular D-serine concentrations in PC-12 cells","volume":"11","author":"Singh","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000149_bib94","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature22084","article-title":"Effects of a ketamine metabolite on synaptic NMDAR function","volume":"546","author":"Suzuki","year":"2017","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000149_bib95","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/elps.201500468","article-title":"Microassay for ketamine and metabolites in plasma and serum based on enantioselective capillary electrophoresis with highly sulfated \u03b3-cyclodextrin and electrokinetic analyte injection","volume":"37","author":"Theurillat","year":"2016","journal-title":"Electrophoresis"},{"key":"10.1124\/pharmrev.120.000149_bib96","doi-asserted-by":"crossref","first-page":"121094","DOI":"10.1016\/j.talanta.2020.121094","article-title":"Separation of anaesthetic ketamine and its derivates in PAMAPTAC coated capillaries with tuneable counter-current electroosmotic flow","volume":"217","author":"T\u016fma","year":"2020","journal-title":"Talanta"},{"key":"10.1124\/pharmrev.120.000149_bib97","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1124\/dmd.108.026328","article-title":"Use of human microsomes and deuterated substrates: an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry","volume":"37","author":"Turfus","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.120.000149_bib98","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.33549\/physiolres.932678","article-title":"Structure, function, and pharmacology of NMDA receptor channels","volume":"63","author":"Vyklicky","year":"2014","journal-title":"Physiol Res"},{"key":"10.1124\/pharmrev.120.000149_bib99","doi-asserted-by":"crossref","first-page":"590221","DOI":"10.3389\/fphar.2020.590221","article-title":"Corticosterone as a potential confounding factor in delineating mechanisms underlying ketamine\u2019s rapid antidepressant actions","volume":"11","author":"Wegman-Points","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1124\/pharmrev.120.000149_bib100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3109\/00498258709043993","article-title":"Biotransformation of ketamine, (Z)-6-hydroxyketamine, and (E)-6-hydroxyketamine by rat, rabbit, and human liver microsomal preparations","volume":"17","author":"Woolf","year":"1987","journal-title":"Xenobiotica"},{"key":"10.1124\/pharmrev.120.000149_bib101","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/s41380-018-0083-8","article-title":"NMDAR-independent, cAMP-dependent antidepressant actions of ketamine","volume":"24","author":"Wray","year":"2019","journal-title":"Mol Psychiatry"},{"key":"10.1124\/pharmrev.120.000149_bib102","doi-asserted-by":"crossref","first-page":"111904","DOI":"10.1016\/j.bbr.2019.111904","article-title":"Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model","volume":"368","author":"Xiong","year":"2019","journal-title":"Behav Brain Res"},{"key":"10.1124\/pharmrev.120.000149_bib103","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41386-018-0084-y","article-title":"(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice","volume":"43","author":"Yamaguchi","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.120.000149_bib104","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.biopsych.2016.12.020","article-title":"(R)-Ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine","volume":"82","author":"Yang","year":"2017","journal-title":"Biol Psychiatry"},{"key":"10.1124\/pharmrev.120.000149_bib105","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/s41398-017-0031-4","article-title":"Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"7","author":"Yang","year":"2017","journal-title":"Transl Psychiatry"},{"key":"10.1124\/pharmrev.120.000149_bib106","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","article-title":"Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"83","author":"Yang","year":"2018","journal-title":"Biol Psychiatry"},{"key":"10.1124\/pharmrev.120.000149_bib107","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl Psychiatry"},{"key":"10.1124\/pharmrev.120.000149_bib108","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/mp.2017.239","article-title":"Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit","volume":"23","author":"Yao","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.1124\/pharmrev.120.000149_bib109","doi-asserted-by":"crossref","first-page":"107667","DOI":"10.1016\/j.neuropharm.2019.107667","article-title":"Ketamine metabolite (2R,6R)-hydroxynorketamine enhances aggression via periaqueductal gray glutamatergic transmission","volume":"157","author":"Ye","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.120.000149_bib110","doi-asserted-by":"crossref","first-page":"172876","DOI":"10.1016\/j.pbb.2020.172876","article-title":"(S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression","volume":"191","author":"Yokoyama","year":"2020","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.120.000149_bib111","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2010.184","article-title":"The role of BDNF in depression on the basis of its location in the neural circuitry","volume":"32","author":"Yu","year":"2011","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/pharmrev.120.000149_bib112","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.1124\/pharmrev.120.000149_bib113","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1111\/bph.14683","article-title":"(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses","volume":"176","author":"Zanos","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.120.000149_bib114","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1073\/pnas.1819540116","article-title":"(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions","volume":"116","author":"Zanos","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000149_bib115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000149_bib116","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1038\/nature22085","article-title":"Zanos et al. reply","volume":"546","author":"Zanos","year":"2017","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000149_bib117","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.120.000149_bib118","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.biopsych.2012.03.004","article-title":"Relationship of ketamine\u2019s plasma metabolites with response, diagnosis, and side effects in major depression","volume":"72","author":"Zarate","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1124\/pharmrev.120.000149_bib119","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1124\/pharmrev.120.000149_bib120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","article-title":"R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine","volume":"116","author":"Zhang","year":"2014","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.120.000149_bib121","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1038\/s41598-018-22449-9","article-title":"Lack of metabolism in (R)-ketamine\u2019s antidepressant actions in a chronic social defeat stress model","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.120.000149_bib122","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1007\/s00213-018-5017-2","article-title":"Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model","volume":"235","author":"Zhang","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.120.000149_bib123","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1365-2125.2012.04198.x","article-title":"Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression","volume":"74","author":"Zhao","year":"2012","journal-title":"Br J Clin Pharmacol"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724006653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724006653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pharmrev.120.000149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T09:17:06Z","timestamp":1739870226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699724006653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":124,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0031699724006653"],"URL":"https:\/\/doi.org\/10.1124\/pharmrev.120.000149","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pharmrev.120.000149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 U.S. Government work not protected by U.S. copyright","name":"copyright","label":"Copyright"}]}}